


J. Russell

Re-run

#17

BIOTECHNOLOGY
SYSTEMS
BRANCH



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/876,257C
Source: 1600
Date Processed by STIC: 3/27/03

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER** **VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



1600

Imported from
 ...
 ...

RAW SEQUENCE LISTING

DATE: 03/27/2003

PATENT APPLICATION: US/09/876,257C

TIME: 12:55:22

Error cap 2

Input Set : A:\SEQUENCE LISTING Of App. No. 09 876,257.txt

Output Set: N:\CRF4\03272003\I876257C.raw

2 <110> APPLICANT: Meloen, Robert H
 3 Oonk, Hendrica B
 5 <120> TITLE OF INVENTION: PEPTIDE, IMMUNOGENIC COMPOSITION AND VACCINE OR
 6 MEDICAL PREPARATION, A METHOD TO IMMUNISE ANIMALS
 7 AGAINST THE HORMONE LHRH, AND ANALOGS OF THE LHRH
 8 TANDEM REPEAT PEPTIDE AND THEIR USE AS VACCINE
 10 <130> FILE REFERENCE: 3516.2US
 12 <140> CURRENT APPLICATION NUMBER: US 09/876,257C
 13 <141> CURRENT FILING DATE: 2001-06-06
 15 <160> NUMBER OF SEQ ID NOS: 7
 16 <170> SOFTWARE: PatentIn version 3.1
 18 <210> SEQ ID NO: 1
 19 <211> LENGTH: 10
 20 <212> TYPE: PRT
 21 <213> ORGANISM: Unknown
 23 <220> FEATURE:
 24 <223> OTHER INFORMATION: Luteinising Hormone Releasing Hormone (LHRH) from the
 25 hypothalamus of an undisclosed mammal.
 27 <220> FEATURE:
 28 <221> NAME/KEY: misc_feature
 29 <222> LOCATION: (1)..(1)
 30 <223> OTHER INFORMATION: X at position 1 = pyroglutamic acid
 32 <220> FEATURE:
 33 <221> NAME/KEY: misc_feature
 34 <222> LOCATION: (10)..(10)
 35 <223> OTHER INFORMATION: X at position 10 = glycine amide
 37 <400> SEQUENCE: 1
 W--> 39 Xaa His Trp Ser Tyr Gly Leu Arg Pro Xaa
 40 1 5 10
 43 <210> SEQ ID NO: 2
 44 <211> LENGTH: 20
 45 <212> TYPE: PRT
 46 <213> ORGANISM: Artificial Sequence
 48 <220> FEATURE:
 49 <223> OTHER INFORMATION: Vaccine against LHRH from the hypothalamus of an
 50 undisclosed mammal.
 52 <220> FEATURE:
 53 <221> NAME/KEY: misc_feature
 54 <222> LOCATION: (1)..(1)
 55 <223> OTHER INFORMATION: X at position 1 = preferably pyroglutamic acid, but can
 56 also be glutamine having attached thereto a tail comprising one or
 57 more additional amino acids
 59 <220> FEATURE:

RAW SEQUENCE LISTING

DATE: 03/27/2003

PATENT APPLICATION: US/09/876,257C

TIME: 12:55:22

Input Set : A:\SEQUENCE LISTING Of App. No. 09 876,257.txt

Output Set: N:\CRF4\03272003\I876257C.raw

60 <221> NAME/KEY: misc_feature
 61 <222> LOCATION: (3)..(3)
 62 <223> OTHER INFORMATION: X at position 3 = tryptophan or formylated tryptophan
 64 <220> FEATURE:
 65 <221> NAME/KEY: misc_feature
 66 <222> LOCATION: (10)..(11)
 67 <223> OTHER INFORMATION: The bond between amino acids 10 and 11 could comprise a
 68 direct peptide bond between 10 and 11 or a spacer consisting
 69 of one or more amino acids, a shorter or longer hydrocarbon
 70 chain, or compound groups or molecules
 72 <220> FEATURE:
 73 <221> NAME/KEY: misc_feature
 74 <222> LOCATION: (13)..(13)
 75 <223> OTHER INFORMATION: X at position 13 = tryptophan or formylated tryptophan
 77 <220> FEATURE:
 78 <221> NAME/KEY: misc_feature
 79 <222> LOCATION: (10)..(20)
 80 <223> OTHER INFORMATION: The sequence comprising residues 10-20 may be repeated.
 82 <220> FEATURE:
 83 <221> NAME/KEY: ~~misc_feature~~
 84 <222> LOCATION: (21)..(21) - *Xaa found at position 20! (anything given is 20)*
 85 <223> OTHER INFORMATION: X at position 21 = either nothing or a tail comprising
 86 additional amino acid; preferably Cys, the C terminal cysteine
 87 being added in connection with a possible coupling of the
 88 peptide to a carrier protein.
 90 <400> SEQUENCE: 2
 W--> 92 Xaa His Xaa Ser Tyr Gly Leu Arg Pro Gly Gln His Xaa Ser Tyr Gly
 93 1 5 10 15
 96 Leu Arg Pro Xaa
 97 20
 100 <210> SEQ ID NO: 3
 101 <211> LENGTH: 21
 102 <212> TYPE: PRT
 103 <213> ORGANISM: Artificial Sequence
 105 <220> FEATURE:
 106 <223> OTHER INFORMATION: Vaccine against LHRH from the
 107 hypothalamus of an undisclosed mammal.
 109 <220> FEATURE:
 110 <221> NAME/KEY: misc_feature
 111 <222> LOCATION: (1)..(1)
 112 <223> OTHER INFORMATION: X at position 1 = pyroglutamic acid
 114 <220> FEATURE:
 115 <221> NAME/KEY: misc_feature
 116 <222> LOCATION: (3)..(3)
 117 <223> OTHER INFORMATION: X at position 3 = tryptophan or N-formyl-Trp
 119 <220> FEATURE:
 120 <221> NAME/KEY: misc_feature
 121 <222> LOCATION: (13)..(13)
 122 <223> OTHER INFORMATION: X at position 13 = tryptophan or N-formyl-Trp

RAW SEQUENCE LISTING

DATE: 03/27/2003

PATENT APPLICATION: US/09/876,257C

TIME: 12:55:22

Input Set : A:\SEQUENCE LISTING Of App. No. 09 876,257.txt

Output Set: N:\CRF4\03272003\I876257C.raw

```

124 <220> FEATURE:
125 <221> NAME/KEY: misc_feature
126 <222> LOCATION: (10)..(19)
127 <223> OTHER INFORMATION: The sequence comprising residues 10-19 may be repeated.
129 <400> SEQUENCE: 3
W--> 131 Xaa His Xaa Ser Tyr Gly Leu Arg Pro Gly Gln His Xaa Ser Tyr Gly
      132 1          5          10          15
      135 Leu Arg Pro Gly Cys
      136          20
      139 <210> SEQ ID NO: 4
      140 <211> LENGTH: 21
      141 <212> TYPE: PRT
      142 <213> ORGANISM: Artificial Sequence
      144 <220> FEATURE:
      145 <223> OTHER INFORMATION: Vaccine against LHRH from the
      146      hypothalamus of an undisclosed mammal.
      148 <220> FEATURE:
      149 <221> NAME/KEY: misc_feature
      150 <222> LOCATION: (1)..(1)
      151 <223> OTHER INFORMATION: X at position 1 = pyroglutamic acid
      153 <220> FEATURE:
      154 <221> NAME/KEY: misc_feature
      155 <222> LOCATION: (6)..(6)
      156 <223> OTHER INFORMATION: X at position 6 = a possible replacement of glycine
      157      by a dextrorotatory amino acid which in addition contains a side
      158      chain by which the LHRH tandem unit can be coupled to a carrier
      159      compound.
      161 <220> FEATURE:
      162 <221> NAME/KEY: misc_feature
      163 <222> LOCATION: (16)..(16)
      164 <223> OTHER INFORMATION: X at position 16 = a possible replacement of
      165      glycine by a dextrorotatory amino acid which in addition contains a side chain
by which the LHRH tandem unit can be coupled to a carrier compound.
      167 <400> SEQUENCE: 4
W--> 169 Xaa His Trp Ser Tyr Xaa Leu Arg Pro Gly Gln His Trp Ser Tyr Xaa
      170 1          5          10          15
      173 Leu Arg Pro Gly Cys
      174          20
      177 <210> SEQ ID NO: 5
      178 <211> LENGTH: 11
      179 <212> TYPE: PRT
      180 <213> ORGANISM: Artificial Sequence
      182 <220> FEATURE:
      183 <223> OTHER INFORMATION: Vaccine against LHRH from the
      184      hypothalamus of an undisclosed mammal.
      186 <220> FEATURE:
      187 <221> NAME/KEY: misc_feature
      188 <222> LOCATION: (1)..(1)
      189 <223> OTHER INFORMATION: X at position 1 = pyroglutamic acid
      191 <220> FEATURE:

```

RAW SEQUENCE LISTING

DATE: 03/27/2003

PATENT APPLICATION: US/09/876,257C

TIME: 12:55:22

Input Set : A:\SEQUENCE LISTING Of App. No. 09 876,257.txt

Output Set: N:\CRF4\03272003\I876257C.raw

```

192 <221> NAME/KEY: misc_feature
193 <222> LOCATION: (6)..(6)
194 <223> OTHER INFORMATION: X at position 6 = Gly or a dextrorotatory amino
195     acid containing a side chain that allows coupling to a carrier
196     compound.
198 <400> SEQUENCE: 5
W--> 200 Xaa His Trp Ser Tyr Xaa Leu Arg Pro Gly Cys
      201 1           5           10
204 <210> SEQ ID NO: 6
205 <211> LENGTH: 21
206 <212> TYPE: PRT
207 <213> ORGANISM: Artificial Sequence
209 <220> FEATURE:
210 <223> OTHER INFORMATION: Vaccine against LHRH from the
211     hypothalamus of an undisclosed mammal.
213 <220> FEATURE:
214 <221> NAME/KEY: misc_feature
215 <222> LOCATION: (21)..(21)
216 <223> OTHER INFORMATION: X at position 21 = glycine amide
218 <220> FEATURE:
219 <221> NAME/KEY: misc_feature
220 <222> LOCATION: (1)..(21)
221 <223> OTHER INFORMATION: The initial cysteine of the peptide comprising
222     residues 1-21 is joined to the initial cysteine of an
223     identical peptide (residues 22-42) to form a dimer.
225 <400> SEQUENCE: 6
227 Cys Gln His Trp Ser Tyr Gly Leu Arg Pro Gly Gln His Trp Ser Tyr
228 1           5           10           15
W--> 231 Gly Leu Arg Pro Xaa
      232           20
235 <210> SEQ ID NO: 7
236 <211> LENGTH: 22
237 <212> TYPE: PRT
238 <213> ORGANISM: Artificial Sequence
240 <220> FEATURE:
241 <223> OTHER INFORMATION: Vaccine against LHRH from the
242     hypothalamus of an undisclosed mammal.
244 <220> FEATURE:
245 <221> NAME/KEY: misc_feature
246 <222> LOCATION: (7)..(7)
247 <223> OTHER INFORMATION: X at position 7 = a possible replacement of glycine
248     by a dextrorotatory amino acid which in addition contains a side
249     chain by which the LHRH tandem unit can be coupled to a carrier
250     compound.
252 <220> FEATURE:
253 <221> NAME/KEY: misc_feature
254 <222> LOCATION: (17)..(17)
255 <223> OTHER INFORMATION: X at position 17 = a possible replacement of
256     glycine by a dextrorotatory amino acid which in addition contains

```

RAW SEQUENCE LISTING

DATE: 03/27/2003

PATENT APPLICATION: US/09/876,257C

TIME: 12:55:22

Input Set : A:\SEQUENCE LISTING Of App. No. 09 876,257.txt

Output Set: N:\CRF4\03272003\I876257C.raw

257 a side chain by which the LHRH tandem unit can be coupled to a
 258 carrier compound.
 260 <220> FEATURE:
 261 <221> NAME/KEY: misc_feature
 262 <222> LOCATION: (1)..(22)
 263 <223> OTHER INFORMATION: The initial cysteine of the peptide comprising
 264 residues 1-22 is joined to the initial cysteine of an identical peptide
 (residues
 265 1-44) to form a dimer.
 267 <400> SEQUENCE: 7
 W--> 269 Cys Gln His Trp Ser Tyr Xaa Leu Arg Pro Gly Gln His Trp Ser Tyr
 270 1 5 10 15
 273 Xaa Leu Arg Pro Gly Cys
 274 20

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/876,257C

DATE: 03/27/2003
TIME: 12:55:23

Input Set : A:\SEQUENCE LISTING Of App. No. 09 876,257.txt
Output Set: N:\CRF4\03272003\I876257C.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1,10
Seq#:2; Xaa Pos. 1,3,13,20
Seq#:3; Xaa Pos. 1,3,13
Seq#:4; Xaa Pos. 1,6,16
Seq#:5; Xaa Pos. 1,6
Seq#:6; Xaa Pos. 21
Seq#:7; Xaa Pos. 7,17

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:4; Line(s) 165
Seq#:7; Line(s) 264

VERIFICATION SUMMARY

DATE: 03/27/2003

PATENT APPLICATION: US/09/876,257C

TIME: 12:55:23

Input Set : A:\SEQUENCE LISTING Of App. No. 09 876,257.txt

Output Set: N:\CRF4\03272003\I876257C.raw

L:39 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0
L:92 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0
M:341 Repeated in SeqNo=2
L:131 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0
L:169 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0
L:200 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:0
L:231 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:16
L:269 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0
M:341 Repeated in SeqNo=7